{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:23Z","timestamp":1740126803388,"version":"3.37.3"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"S 01","funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Corporation","doi-asserted-by":"crossref","award":["A05-130"],"award-info":[{"award-number":["A05-130"]}],"id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Objective\u2003The aim of this study is to compare respiratory illness-related hospitalization (RIH) and respiratory syncytial virus (RSV)-related hospitalization (RSVH) in multiple births versus singletons, who received palivizumab during the RSV season and participated in the Canadian registry of palivizumab (CARESS).<\/jats:p><jats:p>\n          Study Design\u2003Prospective, observational study of infants aged &lt;2 years recruited across 32 centers over 12 RSV seasons from 2005 to 2017. Demographic data were collected at enrolment and RIH events were recorded monthly.<\/jats:p><jats:p>\n          Results\u2003A total of 25,003 infants were enrolled of whom 6,949 (27.8%) were of multiple birth, and 18,054 (72.2%) were singletons. A significantly larger proportion of the multiple births were premature (80.2%) compared with the singleton group (56.8%). Multiples had a lower gestational age (mean\u2009\u00b1\u2009standard deviation): 31.2\u2009\u00b1\u20093.2 versus 33.2\u2009\u00b1\u20095.5 weeks and birth weight (mean: 1,590\u2009\u00b1\u2009606.8 vs. 2,069.4\u2009\u00b1\u20091068.5\u2009g; both p\u2009&lt;\u20090.0005). They were younger at enrolment (4.5\u2009\u00b1\u20095.0 vs. 6.1\u2009\u00b1\u20096.8 months), and fewer attended daycare (1.9 vs. 4.6%), and experienced exposure to smoking (24.5 vs. 29.9%), but more lived in a crowded household (36.7 vs. 19.4%); all p\u2009&lt;\u20090.0005. Multiples had a longer length of neonatal stay (51.1\u2009\u00b1\u200965.9 vs. 47.9\u2009\u00b1\u200967.8 days), and more required respiratory support (65.7 vs. 57.7%), but for shorter duration (22.6\u2009\u00b1\u200932.9 vs. 24.7\u2009\u00b1\u200940.6 days); all p\u2009&lt;\u20090.001. RIH and RSVH rates (%) in multiples versus singletons were 4.7; 7.7 and 1.4; and 1.6, respectively. Cox regression showed that multiples had a lower risk of RIH compared with singletons (hazard ratio [HR]\u2009=\u20090.616, 95% confidence interval [CI]: 0.543\u20130.698, p\u2009&lt;\u20090.0005), but not RSVH (HR: 0.77, 95% CI: 0.57\u20131.02, p\u2009=\u20090.071).<\/jats:p><jats:p>\n          Conclusion\u2003Multiple birth infants, who are known to be at greater risk for severe RSVH compared with singletons, are well protected by palivizumab, provided adherence to the monthly injection scheme is guaranteed.<\/jats:p>","DOI":"10.1055\/s-0040-1708804","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:30:46Z","timestamp":1585697446000},"page":"e129-e136","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab"],"prefix":"10.1055","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3308-2706","authenticated-orcid":false,"given":"Bosco","family":"Paes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Outcomes and Research in Economics Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Outcomes and Research in Economics Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista L.","family":"Lanctot","sequence":"additional","affiliation":[{"name":"Medical Outcomes and Research in Economics Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-1050","authenticated-orcid":false,"given":"Ian","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CARESS Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"020416","DOI":"10.7189\/jogh.05.020416","article-title":"Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis","volume":"5","author":"T Shi","year":"2015","journal-title":"J Glob Health"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease","volume":"5","author":"J Figueras-Aloy","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0038-1660466","article-title":"Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012\u20132016","volume":"35","author":"M Goldstein","year":"2018","journal-title":"Am J Perinatol"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"e0166226","DOI":"10.1371\/journal.pone.0166226","article-title":"Effects of chronologic age and young child exposure on respiratory syncytial virus disease among US preterm infants born at 32 to 35 weeks gestation","volume":"11","author":"E A Sim\u00f5es","year":"2016","journal-title":"PLoS One"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0036-1584147","article-title":"SENTINEL1: An observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis","volume":"34","author":"E J Anderson","year":"2017","journal-title":"Am J Perinatol"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/jp.2016.113","article-title":"Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants","volume":"36","author":"K K McLaurin","year":"2016","journal-title":"J Perinatol"},{"issue":"01","key":"ref7","first-page":"1","article-title":"Births: final data for 2016","volume":"67","author":"J A Martin","year":"2018","journal-title":"Natl Vital Stat Rep"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.siny.2012.01.012","article-title":"Impact of multiple births on late and moderate prematurity","volume":"17","author":"J S Refuerzo","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.semperi.2006.03.001","article-title":"Multiple gestations and late preterm (near-term) deliveries","volume":"30","author":"Y M Lee","year":"2006","journal-title":"Semin Perinatol"},{"issue":"12","key":"ref10","first-page":"1188","article-title":"The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age","volume":"25","author":"G Doering","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jinf.2004.06.015","article-title":"Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age","volume":"50","author":"B Resch","year":"2005","journal-title":"J Infect"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJWH.S16608","article-title":"Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation","volume":"3","author":"K L Gooch","year":"2011","journal-title":"Int J Womens Health"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1097\/INF.0b013e318257f619","article-title":"Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age","volume":"31","author":"H W Park","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archpedi.1993.02160270065020","article-title":"Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection","volume":"147","author":"E A Simoes","year":"1993","journal-title":"Am J Dis Child"},{"issue":"11","key":"ref15","first-page":"701","article-title":"Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins","volume":"15","author":"M Dotan","year":"2013","journal-title":"Isr Med Assoc J"},{"issue":"03","key":"ref16","first-page":"121","article-title":"[Quality of life of preterm infants and admissions due to respiratory infections]","volume":"73","author":"I M\u00e9ndez Rubio","year":"2010","journal-title":"An Pediatr (Barc)"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/ped.12200","article-title":"Apnea with RSV infection in three infants receiving palivizumab","volume":"55","author":"M T Del Vecchio","year":"2013","journal-title":"Pediatr Int"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"ref19","first-page":"43","article-title":"Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the Impact-RSV trial by gestational age group","volume":"5","author":"G Notario","year":"2014","journal-title":"Pediatric Health Med Ther"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-3476(76)80918-3","article-title":"Respiratory syncytial virus infections in infants: quantitation and duration of shedding","volume":"89","author":"C B Hall","year":"1976","journal-title":"J Pediatr"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/infdis\/141.1.98","article-title":"Possible transmission by fomites of respiratory syncytial virus","volume":"141","author":"C B Hall","year":"1980","journal-title":"J Infect Dis"},{"issue":"08","key":"ref22","first-page":"329","article-title":"Excretion patterns of human metapneumovirus and respiratory syncytial virus among young children","volume":"11","author":"M L von Linstow","year":"2006","journal-title":"Eur J Med Res"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/INF.0b013e31821146f7","article-title":"CARESS: the Canadian registry of palivizumab","volume":"30","author":"I Mitchell","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/INF.0000000000002297","article-title":"Respiratory syncytial virus prophylaxis in neurologic and muscular disorders in the Canadian respiratory syncytial virus evaluation study of palivizumab","volume":"38","author":"D Y Wang","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","article-title":"Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of palivizumab","volume":"34","author":"P Chan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children","volume":"56","author":"G J Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2013.03.007","article-title":"Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis","volume":"26","author":"W V La Via","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2018.1401926","article-title":"Adherence and outcomes: a systematic review of palivizumab utilization","volume":"12","author":"S K Wong","year":"2018","journal-title":"Expert Rev Respir Med"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/INF.0000000000000219","article-title":"Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis","volume":"33","author":"C S Ambrose","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/adc.2003.028282","article-title":"Lower respiratory tract illness and RSV prophylaxis in very premature infants","volume":"89","author":"T Lacaze-Masmonteil","year":"2004","journal-title":"Arch Dis Child"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1542\/peds.2007-1889","article-title":"Increased concordance of severe respiratory syncytial virus infection in identical twins","volume":"121","author":"S F Thomsen","year":"2008","journal-title":"Pediatrics"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1164\/rccm.201509-1833OC","article-title":"Evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies?","volume":"194","author":"H Kulkarni","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40121-016-0137-7","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease","volume":"5","author":"B Paes","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40121-016-0142-x","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease","volume":"6","author":"P A Checchia","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40121-017-0160-3","article-title":"Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases","volume":"6","author":"P Manzoni","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10096-018-3409-1","article-title":"Respiratory syncytial virus (RSV) infection in children with medical complexity","volume":"38","author":"A Lim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref37","first-page":"e28","article-title":"Use of palivizumab in Canada: Data from the CARESS registry 2005\u20132017","volume":"24","author":"I Mitchell","year":"2019","journal-title":"Paediatr Child Health"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1708804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:59:58Z","timestamp":1730822398000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1708804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":37,"journal-issue":{"issue":"S 01","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1708804","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"type":"print","value":"0735-1631"},{"type":"electronic","value":"1098-8785"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}